Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 194  

 
   Table of Contents      
LETTER TO EDITOR
Year : 2014  |  Volume : 13  |  Issue : 3  |  Page : 209

Bone metastases treatment by Sm-153 oxabifore in combination with monoclonal antibody denosumab (Xgeva)


1 Department of Medical Center, Sanitation 1 Medical Academic Center, Bangkok, Thailand
2 Department of Tropical Medicine, Joseph Ayo Babalola University, Osun State, Nigeria

Date of Web Publication15-Nov-2014

Correspondence Address:
Login to access the Email id


DOI: 10.4103/1450-1147.144825

PMID: 25538496

Rights and Permissions

How to cite this article:
Joob B, Wiwanitkit V. Bone metastases treatment by Sm-153 oxabifore in combination with monoclonal antibody denosumab (Xgeva). World J Nucl Med 2014;13:209

How to cite this URL:
Joob B, Wiwanitkit V. Bone metastases treatment by Sm-153 oxabifore in combination with monoclonal antibody denosumab (Xgeva). World J Nucl Med [serial online] 2014 [cited 2019 Dec 15];13:209. Available from: http://www.wjnm.org/text.asp?2014/13/3/209/144825

To the Editor,

A recent report on "bone metastases treatment by samarium (sm)-153 oxabifore in combination with monoclonal antibody denosumab (Xgeva)" is very interesting. [1] Rasulova et al. noted that "combined treatment of bone metastases with sm-153 oxabifore and denosumab is effective and safe. [1]" In fact, the combination is very interesting. A similar observation was also reported by Rasulova et al. on another combination between sm-153 oxabifore and bisphosphonate. Focusing on the present combination, sm-153 oxabifore and denosumab, the issue of side-effect should be studied in a larger scale. In fact, denosumab is generally used for management of bone loss in cancer patients. [2] However, some interesting side-effect of this drug can be seen. The important condition is osteonecrosis. [3],[4] For sm-153, the effectiveness and side-effect is still inconclusive. The flare up of pain can be possible during therapy. As already note, further studies are still required for conclusion (see a clinical report in Russian language: base.ukgma.kz/vestnik/2012/vestnik_3_12.doc).

 
   References Top

1.Rasulova N, Lyubshin V, Arybzhanov D, Krylov V, Khodjibekov M. Effectiveness of bone metastases treatment by sm-153 oxabifore in combination with monoclonal antibody denosumab (xgeva): First experience. World J Nucl Med 2013;12:19-23.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.Rasulova N, Lyubshin V, Arybzhanov D, Sagdullaev Sh, Krylov V, Khodjibekov M. Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone disease. World J Nucl Med 2013;12:14-8.  Back to cited text no. 2
[PUBMED]  Medknow Journal  
3.Yee AJ, Raje NS. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging 2012;7:331-8.  Back to cited text no. 3
    
4.Aghaloo TL, Dry SM, Mallya S, Tetradis S. Stage 0 osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg 2014;72:702-16.  Back to cited text no. 4
    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed946    
    Printed30    
    Emailed0    
    PDF Downloaded127    
    Comments [Add]    

Recommend this journal